SunDomaTM is a super high affinity antibody R&D technology platform developed by Longbio Pharma.
The technology is developed based on the more than 30 years of experience in hybridoma technology by its founder Dr. Sun Naichao. Based on this platform, Longbio Pharma has developed a new generation of IgE antibody LP-003.
| Target | SunDomaTM | Competitors |
|---|---|---|
| IgE | 2.08 pM | 1780 pM |
| IL-5 | 1.68 pM | 227.71 pM |
| NGF | 14.36 pM | 91.3 pM |
InCibitorTM is a new generation of complement inhibitor platform independently developed by Longbio Pharma.
The bi-functional complement inhibitor LP-005 developed based on this platform is going to start Phase II study.
Longbio Pharma is also exploring the development of drugs related to hematology, nephrology, neurology, ophthalmology, oncology, and gene therapy based on this platform.
High complement inhibition, both in AP (alternative pathway), CP (classical pathway) and LP (lectin pathway)
~20Kd，excellent tissue penetration
Great drug properties with optimized solubility
Good performance on PK/PD
Paroxysmal nocturnal hemoglobinuria (PNH)
Generalized myasthenia gravis (gMG)
Amyotrophic lateral sclerosis (ALS)
Myelin-associated glycoprotein associated neuropathies (MAG-PN)
IgA nephropathy (IgAN)
Lupus nephropathy (LN)
C3 glomerulopathy (C3G)
Dry AMD
AAV-based (new sequence)
Oncolytic virus
Combined with I/O
NeXineTM is the next-generation long-acting cytokine technology platform independently developed by Longbio Pharma.
The platform is based on the co-founder, Dr. Sun’s fc-fusion protein technology, and multiple candidate cytokine drug molecules have been developed based on this platform.
Dosing interval of Long acting cytokine that developed
by
NeXineTM platform
| Cytokine | NeXineTM | Competitors (Long-acting) |
|---|---|---|
| Growth hormone (GH) | Q2W-Q4W | Q1W |
| Erythropoietin (EPO) | Q4W | Q2W-Q3W |
| Insulin | Q2W | QD |
| Coagulation factor VIII | Q1W-Q2W | BIW |
